Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart failure

- PMLiVE

Heart research campaign urges chocolate detox for workers

British Heart Foundation hopes to inspire officer workers to abstain in March

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Novartis building

Novartis boosts cardiovascular pipeline with $1bn Ionis deal

Gains rights to two lipoprotein-targeting drugs currently in early-stage clinical development 

- PMLiVE

Novartis launches heart failure social network

Together in HF is the first digital effort of its kind for the condition

Sanofi reception

Sanofi launches insulin combo Soliqua in US

Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

Bayer symbol

Bayer helps bankroll new stem cell company BlueRock

Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

- PMLiVE

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Licenses two gene silencing programmes with up to $670m in the offing for the specialist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links